Cumberland Partners Ltd grew its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 46.9% during the first quarter, HoldingsChannel.com reports. The firm owned 191,855 shares of the biopharmaceutical company’s stock after buying an additional 61,285 shares during the period. Cumberland Partners Ltd’s holdings in Pfizer were worth $5,387,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the fourth quarter valued at about $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer during the 4th quarter worth about $28,000. HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the period. Evolution Wealth Management Inc. increased its stake in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $31,000. 68.36% of the stock is currently owned by institutional investors.
Trending Headlines about Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer announced that PF-08057418 cleared a Phase 1 safety milestone, which helps reinforce confidence in the company’s research pipeline and early-stage development prospects. Article: Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence
- Positive Sentiment: Pfizer is advancing PF-08653945 into an early-stage obesity trial, giving investors another potential growth driver in a large and competitive therapeutic market. Article: Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945
- Positive Sentiment: The FDA granted Priority Review to Pfizer’s Talzenna plus Xtandi regimen for metastatic prostate cancer, which improves the odds of a faster regulatory decision and supports oncology revenue upside if approved. Article: FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
- Neutral Sentiment: Unusual call option activity suggests traders are positioning for a move in Pfizer shares, but it does not by itself confirm a fundamental change in the company’s outlook.
- Neutral Sentiment: Recent commentary on Pfizer’s dividend yield and oncology valuation highlights that investors are still weighing income appeal against execution and growth concerns.
- Negative Sentiment: Expanded patent litigation tied to Pfizer’s mRNA vaccine business remains a potential overhang, adding legal and operational uncertainty that could pressure sentiment if the dispute escalates. Article: Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside
Analyst Ratings Changes
Pfizer Stock Down 1.9%
Pfizer stock opened at $24.52 on Friday. The company has a 50 day moving average of $25.11 and a 200-day moving average of $26.16. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The stock has a market capitalization of $139.78 billion, a PE ratio of 18.72 and a beta of 0.35.
Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is 131.30%.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
